Riskpilot← Back to searchSign inGet full accessNan Medical AB
ABActiveOrg 5591965255Storbergsgatan 34General medical practice activities · NACE 8621Est. 20190 employees
Revenue 2025
SEK 0
EBITDA margin
—
+76% vs 2024
Equity ratio
100.0%
Financial strength
Net profit 2025
SEK 122K
-51% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -18K | +76% |
| Net profit | SEK 122K | -51% |
| Total assets | SEK 19,4M | +0% |
| Equity | SEK 19,4M | +1% |
| Employees | 0 | — |
Legal name
Nan Medical AB
Org number
5591965255
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
27 februari 2019
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva läkarbehandlingar inom slutenvårds- kliniker för somatisk sjukvård och specialistläkarmottagningar inom öppenvård inom gynekologi, barn, hud, ortopedi, samt öron, näsa, hals och ögonmottagningen samt import och export av läkemedel och instrument som är avsedda att användas på sjukhus, men kan också vara en del av ambulansbilarnas utrustning.
Address
Storbergsgatan 34
Email
lazhakadir@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 25 | 0 | 0 |
| Staff expenses | — | — | — | −0 | — |
| EBITDA | −8 | −1 | −683 | −76 | −18 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −8 | −1 | −683 | −76 | −18 |
| Net financials | 6 788 | 3 960 | 240 | 325 | 140 |
| Profit before tax | 8 022 | 3 959 | −442 | 248 | 122 |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | 8 022 | 3 959 | −442 | 248 | 122 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 18 071 | 20 710 | 19 050 | 19 326 | 19 387 |
| Equity | 18 071 | 20 710 | 19 016 | 19 264 | 19 386 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 0 | 0 | 34 | 62 | 1 |
| Total debt | — | — | 34 | 62 | 1 |
EBITDA margin
-1794500.0%
This company
15.8%
Market median
-11357695% vs market
20212025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20212025
Return on equity
0.6%
This company
18.4%
Market median
-97% vs market
20212025
Net profit margin
12209900.0%
This company
8.1%
Market median
+150739406% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
LE Audit | Audit | 2022 – 2025 |
AM Auditor Substitute | Auditor Substitute | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nan Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars-Erik Engberg | Audit | 0 companies |
| Anna Maria Wretholm | Auditor Substitute | 0 companies |
| Lazha Kadir | Board of Directors | 0 companies |
| Awder Mustafa | Deputy Board Member | 0 companies |